Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective

Costs of hemophilia A treatment are increasing. Waste of clotting products should be avoided. To estimate the first-year waste of emicizumab prophylaxis for people with hemophilia A and inhibitors (PwHAi) who failed immune tolerance induction (ITI), in Brazil. We evaluated the manufacturer and the B...

Descripción completa

Detalles Bibliográficos
Autores principales: Camelo, Ricardo Mesquita, Barbosa, Mariana Michel, Henriques, Luila Clicia Moura, Martin, Antony Paul, Godman, Brian, Guerra Júnior, Augusto Afonso, Acurcio, Francisco de Assis, Alvares-Teodoro, Juliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661532/
https://www.ncbi.nlm.nih.gov/pubmed/38028212
http://dx.doi.org/10.1016/j.jsps.2023.101867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661532/
https://www.ncbi.nlm.nih.gov/pubmed/38028212
http://dx.doi.org/10.1016/j.jsps.2023.101867

Ejemplares similares